Introduction
Adipotide and AOD 9604 both target adipose tissue reduction, but through radically different mechanisms. Adipotide (CKGGRAKDC-GG-D(KLAKLAK)2) is a peptidomimetic that selectively induces apoptosis in the blood vessels supplying white adipose tissue, causing fat cells to die from ischemia. AOD 9604 is a GH-fragment peptide that enhances lipolysis — the breakdown of stored triglycerides — without killing fat cells. These approaches differ not only in mechanism but in reversibility, safety profile, and research implications.
Mechanism of Action Comparison
Adipotide is a chimeric peptide containing a targeting domain (CKGGRAKDC) that binds prohibitin on the surface of blood vessels supplying white adipose tissue, fused to a pro-apoptotic domain (D(KLAKLAK)2) that disrupts mitochondrial membranes upon internalization. By cutting off blood supply to fat deposits, adipotide causes adipocyte death through ischemia. This mechanism produces irreversible fat loss — the fat cells are destroyed, not merely emptied of stored lipid.
AOD 9604 mimics the C-terminal lipolytic domain of human growth hormone (amino acids 176-191), stimulating beta-3 adrenergic receptor-mediated lipolysis. Fat cells release their stored triglycerides for oxidation but remain alive and capable of re-accumulating lipid if energy balance shifts. The mechanism is pharmacological rather than destructive, making it reversible and generally considered safer.
Key Differences
| Feature | Adipotide | AOD 9604 |
|---|---|---|
| Mechanism | Vascular targeting + apoptosis | Lipolysis (GH fragment activity) |
| Fat Cell Fate | Killed (irreversible) | Emptied (reversible) |
| Selectivity | White adipose tissue vasculature | Adipose tissue broadly |
| Safety Concerns | Renal toxicity reported in primates | Minimal in clinical trials |
| Clinical Status | Preclinical (animal studies) | Phase 2 completed (humans) |
| IGF-1 Effects | None | None |
| Reversibility | Irreversible fat loss | Reversible without continued use |
Research Applications
Adipotide is studied in targeted drug delivery research, vascular-targeted apoptosis, morbid obesity models, and cancer biology (the vascular targeting approach parallels anti-tumor strategies). Its mechanism is potent but carries significant safety concerns including renal toxicity observed in primate studies. AOD 9604 is investigated in obesity, body composition, cartilage repair, and osteoarthritis, with a well-characterized safety profile from human clinical trials.
Which to Choose for Your Research?
For mechanistic research on targeted vascular apoptosis in adipose tissue, adipotide provides a unique and powerful tool, though its toxicity profile limits translational potential. For translational fat loss research with human safety data, AOD 9604 offers a well-characterized, lower-risk approach. Most metabolic researchers favor AOD 9604 or GLP-1 agonists (Semaglutide, Tirzepatide) for practical fat loss studies, reserving adipotide for targeted drug delivery or vascular biology investigations.
